CA3242384A1 - Carbonic anhydrase ix ligands - Google Patents
Carbonic anhydrase ix ligandsInfo
- Publication number
- CA3242384A1 CA3242384A1 CA3242384A CA3242384A CA3242384A1 CA 3242384 A1 CA3242384 A1 CA 3242384A1 CA 3242384 A CA3242384 A CA 3242384A CA 3242384 A CA3242384 A CA 3242384A CA 3242384 A1 CA3242384 A1 CA 3242384A1
- Authority
- CA
- Canada
- Prior art keywords
- caix
- peptide
- compound
- compositions
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/086592 | 2021-12-17 | ||
| EP2021086592 | 2021-12-17 | ||
| EP2022054857 | 2022-02-25 | ||
| EPPCT/EP2022/054857 | 2022-02-25 | ||
| EP2022057170 | 2022-03-18 | ||
| EPPCT/EP2022/057170 | 2022-03-18 | ||
| EP2022057840 | 2022-03-24 | ||
| EPPCT/EP2022/057840 | 2022-03-24 | ||
| EPPCT/EP2022/067424 | 2022-06-24 | ||
| EP2022067424 | 2022-06-24 | ||
| EPPCT/EP2022/079606 | 2022-10-24 | ||
| EP2022079606 | 2022-10-24 | ||
| EPPCT/EP2022/081674 | 2022-11-11 | ||
| EP2022081674 | 2022-11-11 | ||
| PCT/EP2022/086632 WO2023111350A2 (en) | 2021-12-17 | 2022-12-19 | Carbonic anhydrase ix ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242384A1 true CA3242384A1 (en) | 2023-06-22 |
Family
ID=84981172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242384A Pending CA3242384A1 (en) | 2021-12-17 | 2022-12-19 | Carbonic anhydrase ix ligands |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250339569A1 (enExample) |
| EP (1) | EP4448544A2 (enExample) |
| JP (1) | JP2025503451A (enExample) |
| KR (1) | KR20240133798A (enExample) |
| AR (1) | AR128023A1 (enExample) |
| AU (1) | AU2022410422B2 (enExample) |
| CA (1) | CA3242384A1 (enExample) |
| CL (1) | CL2024001830A1 (enExample) |
| IL (1) | IL313536A (enExample) |
| MA (1) | MA66591A1 (enExample) |
| MX (1) | MX2024007454A (enExample) |
| TW (1) | TW202340226A (enExample) |
| WO (1) | WO2023111350A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4321526A4 (en) * | 2022-02-11 | 2026-04-15 | C Biomex Co Ltd | Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses |
| JP2026522427A (ja) * | 2023-06-20 | 2026-07-07 | デバイオファーム インターナショナル エス．エー． | 炭酸脱水酵素ｉｘ陽性疾患の治療方法で用いるための放射性標識化合物 |
| AU2024298898A1 (en) * | 2023-07-25 | 2025-11-27 | C-Biomex Co., Ltd. | Peptide structure targeting carbonic dehydrogenase ix and use thereof |
| WO2026125277A1 (en) * | 2024-12-09 | 2026-06-18 | Debiopharm International S.A. | Combination of carbonic anhydrase ix ligands |
| CN120943901A (zh) * | 2025-05-29 | 2025-11-14 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2012016713A1 (en) | 2010-08-05 | 2012-02-09 | Ruprecht-Karls-Universität Heidelberg | Tumour targeting with polypeptides |
| US9238676B2 (en) * | 2012-05-17 | 2016-01-19 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| EP3442991A4 (en) * | 2016-04-15 | 2019-11-20 | RA Pharmaceuticals, Inc. | RAS-BINDING PEPTIDES AND METHODS OF USE |
| TW201919682A (zh) * | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| CA3082271A1 (en) | 2017-11-14 | 2019-05-23 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| GB201900525D0 (en) * | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for caix |
| GB201900526D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
| CN118955620A (zh) * | 2019-07-08 | 2024-11-15 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| TWI765195B (zh) | 2019-11-22 | 2022-05-21 | 行政院原子能委員會核能研究所 | 雙靶向碳酸酐酶第九型複合物及其造影劑 |
-
2022
- 2022-12-19 EP EP22843649.9A patent/EP4448544A2/en active Pending
- 2022-12-19 IL IL313536A patent/IL313536A/en unknown
- 2022-12-19 WO PCT/EP2022/086632 patent/WO2023111350A2/en not_active Ceased
- 2022-12-19 JP JP2024536171A patent/JP2025503451A/ja active Pending
- 2022-12-19 KR KR1020247023840A patent/KR20240133798A/ko active Pending
- 2022-12-19 US US18/720,400 patent/US20250339569A1/en active Pending
- 2022-12-19 AR ARP220103498A patent/AR128023A1/es unknown
- 2022-12-19 AU AU2022410422A patent/AU2022410422B2/en active Active
- 2022-12-19 CA CA3242384A patent/CA3242384A1/en active Pending
- 2022-12-19 MX MX2024007454A patent/MX2024007454A/es unknown
- 2022-12-19 TW TW111148813A patent/TW202340226A/zh unknown
- 2022-12-19 MA MA66591A patent/MA66591A1/fr unknown
-
2024
- 2024-06-17 CL CL2024001830A patent/CL2024001830A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4448544A2 (en) | 2024-10-23 |
| WO2023111350A2 (en) | 2023-06-22 |
| WO2023111350A3 (en) | 2023-07-27 |
| AU2022410422A1 (en) | 2024-07-04 |
| CL2024001830A1 (es) | 2024-12-06 |
| JP2025503451A (ja) | 2025-02-04 |
| IL313536A (en) | 2024-08-01 |
| TW202340226A (zh) | 2023-10-16 |
| MX2024007454A (es) | 2024-09-02 |
| AR128023A1 (es) | 2024-03-20 |
| KR20240133798A (ko) | 2024-09-04 |
| US20250339569A1 (en) | 2025-11-06 |
| AU2022410422B2 (en) | 2026-01-08 |
| MA66591A1 (fr) | 2025-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023111350A3 (en) | Carbonic anhydrase ix ligands | |
| EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
| WO2005116051A3 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| CA2548915A1 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| PH12012501687B1 (en) | Acetylcysteine composition and uses therefor | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EP2384740A3 (en) | Oral care product and methods of use and manufacture thereof | |
| WO2007102686A8 (en) | Peptides having activities of insulin like growth factor-1 and their uses | |
| WO2007112000A3 (en) | Treatment of pain | |
| EA200500300A1 (ru) | Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение | |
| IL164440A0 (en) | New pharmaceutical composition containing fibanserin polymorph a | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| TW200639159A (en) | Treatment of pain | |
| KR20130049640A (ko) | 구강유용물질을 포함하는 구강용 캡슐 및 그 제조방법 | |
| EA200801305A1 (ru) | Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| MY140105A (en) | 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts | |
| PL372492A1 (en) | Muteins of placental growth factor type 1, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240730 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |